摘要:
The present invention relates to antibodies specifically binding PD-1, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
摘要:
Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
摘要:
The present invention relates to antibodies specifically binding PD-1, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
摘要:
The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
摘要:
Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
摘要:
An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
摘要:
Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.
摘要:
The invention provides methods for testing and ranking therapeutic antibody candidates for biophysical properties related to solubility and the susceptibility of the antibody to aggregate in aqueous solutions. The methods are useful for selecting among antibody libraries or variants for candidates which can be formulated at high concentrations.